Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 11263

1.

Regulatory Cascade of Neuronal Loss and Glucose Metabolism.

Hassan M, Sehgal SA, Rashid S.

CNS Neurol Disord Drug Targets. 2014 Sep 17. [Epub ahead of print]

PMID:
25230224
[PubMed - as supplied by publisher]
2.

Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?

Tata AM, Velluto L, D'Angelo C, Reale M.

CNS Neurol Disord Drug Targets. 2014 Sep 17. [Epub ahead of print]

PMID:
25230223
[PubMed - as supplied by publisher]
3.

Growth characteristics of different heart cells on novel nanopatch substrate during electrical stimulation.

Stout DA, Raimondo E, Marostica G, Webster TJ.

Biomed Mater Eng. 2014 Jan 1;24(6):2101-7. doi: 10.3233/BME-141020.

PMID:
25226907
[PubMed - in process]
4.

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System.

Janssens J, Etienne H, Idriss S, Azmi A, Martin B, Maudsley S.

Front Endocrinol (Lausanne). 2014 Sep 1;5:142. doi: 10.3389/fendo.2014.00142. eCollection 2014. Review.

PMID:
25225492
[PubMed]
Free PMC Article
5.

Safety, Pharmacokinetics, Pharmacogenomics and QT Concentration Effect Modelling of the SirT1 Inhibitor Selisistat in Healthy Volunteers.

Westerberg G, Chiesa JA, Andersen CA, Diamanti D, Magnoni L, Pollio G, Darpo B, Zhou M.

Br J Clin Pharmacol. 2014 Sep 16. doi: 10.1111/bcp.12513. [Epub ahead of print]

PMID:
25223836
[PubMed - as supplied by publisher]
6.

An Exploratory Double blind, Randomised Clinical Trial with Selisistat, a SirT1 Inhibitor, in Patients with Huntington's Disease.

Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, Saft C, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G; PADDINGTON Consortium.

Br J Clin Pharmacol. 2014 Sep 16. doi: 10.1111/bcp.12512. [Epub ahead of print]

PMID:
25223731
[PubMed - as supplied by publisher]
7.

YKL-40 in cerebrospinal fluid in Huntington's disease - A role in pathology or a nonspecific response to inflammation?

Vinther-Jensen T, Budtz-Jørgensen E, Simonsen AH, Nielsen JE, Hjermind LE.

Parkinsonism Relat Disord. 2014 Aug 28. pii: S1353-8020(14)00309-5. doi: 10.1016/j.parkreldis.2014.08.011. [Epub ahead of print] No abstract available.

PMID:
25219973
[PubMed - as supplied by publisher]
8.

Disruption of striatal-enriched protein tyrosine phosphatase (STEP) function in neuropsychiatric disorders.

Karasawa T, Lombroso PJ.

Neurosci Res. 2014 Sep 10. pii: S0168-0102(14)00211-9. doi: 10.1016/j.neures.2014.08.018. [Epub ahead of print] Review.

PMID:
25218562
[PubMed - as supplied by publisher]
9.

Epigenetic mechanisms in the development of memory and their involvement in certain neurological diseases.

Rosales-Reynoso MA, Ochoa-Hernández AB, Juárez-Vázquez CI, Barros-Núñez P.

Neurologia. 2014 Sep 9. pii: S0213-4853(14)00031-0. doi: 10.1016/j.nrl.2014.02.004. [Epub ahead of print] English, Spanish.

PMID:
25217064
[PubMed - as supplied by publisher]
Free Article
10.

Stem cells for cell replacement therapy: A therapeutic strategy for HD?

Rosser A, Svendsen CN.

Mov Disord. 2014 Sep 15;29(11):1446-54. doi: 10.1002/mds.26026.

PMID:
25216372
[PubMed - in process]
11.

Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.

Sampaio C, Borowsky B, Reilmann R.

Mov Disord. 2014 Sep 15;29(11):1419-28. doi: 10.1002/mds.26021.

PMID:
25216371
[PubMed - in process]
12.

Preclinical models: Needed in translation? A Pro/Con debate.

Philips T, Rothstein JD, Pouladi MA.

Mov Disord. 2014 Sep 15;29(11):1391-6. doi: 10.1002/mds.26010.

PMID:
25216370
[PubMed - in process]
13.

Animal models of Huntington's disease for translation to the clinic: Best practices.

Menalled L, Brunner D.

Mov Disord. 2014 Sep 15;29(11):1375-90. doi: 10.1002/mds.26006.

PMID:
25216369
[PubMed - in process]
14.

In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in huntington's disease.

Müller S.

Transl Neurodegener. 2014 Aug 18;3:17. doi: 10.1186/2047-9158-3-17. eCollection 2014.

PMID:
25210621
[PubMed]
Free PMC Article
15.

A targets framework: Dismantling the invisibility trap for children with drug-resistant tuberculosis.

Becerra MC, Swaminathan S.

J Public Health Policy. 2014 Sep 11. doi: 10.1057/jphp.2014.35. [Epub ahead of print]

PMID:
25209537
[PubMed - as supplied by publisher]
16.

HD-CAB: A cognitive assessment battery for clinical trials in Huntington's disease(1,2,3.).

Stout JC, Queller S, Baker KN, Cowlishaw S, Sampaio C, Fitzer-Attas C, Borowsky B; HD-CAB Investigators.

Mov Disord. 2014 Sep;29(10):1281-8. doi: 10.1002/mds.25964. Epub 2014 Jul 7.

PMID:
25209258
[PubMed - in process]
17.

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all huntington disease patients.

Skotte NH, Southwell AL, Ostergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, Hayden MR.

PLoS One. 2014 Sep 10;9(9):e107434. doi: 10.1371/journal.pone.0107434. eCollection 2014.

PMID:
25207939
[PubMed - in process]
Free PMC Article
18.

Examination of Huntington's disease in a Chinese family.

Yu M, Li X, Wu S, Shen J, Tu J.

Neural Regen Res. 2014 Feb 15;9(4):440-6. doi: 10.4103/1673-5374.128258.

PMID:
25206833
[PubMed]
Free PMC Article
19.

The mechanism of degeneration of striatal neuronal subtypes in Huntington disease.

Rikani AA, Choudhry Z, Choudhry AM M B B S, Rizvi N, Ikram H, Mobassarah NJ, Tulli S.

Ann Neurosci. 2014 Jul;21(3):112-114. Review.

PMID:
25206077
[PubMed - as supplied by publisher]
Free PMC Article
20.

A case of familial ALS due to multi-system proteinopathy 1 and Huntington disease.

Oskarsson B, Wheelock V, Benatar M, Taylor JP, Joyce N, Chesak D, Jin LW.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep 10:1-3. [Epub ahead of print] No abstract available.

PMID:
25205077
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk